Skip to main content
Colorado General AssemblyToggle Main Menu
Agency NameToggle Agency Menu

BF76CCF04E2498068725898F005DCDAC Hearing Summary




PUBLIC
BILL SUMMARY For HB23-1002

SENATE COMMITTEE ON HEALTH & HUMAN SERVICES
Date Apr 12, 2023      
Location SCR 357



HB23-1002 - Amended, referred to Senate Appropriations

11:04:38 AM  
Senator Roberts, prime bill sponsor, presented House Bill 23-1002, concerning creating an epinephrine auto-injector affordability program in the Department of Regulatory Agencies (DORA) to provide low-cost epinephrine auto-injectors to eligible individuals in the state. The bill outlines the individuals eligible to participate in the program and requires the Division of Insurance (DOI) within DORA to create an application form for the program. This form is to be made available and promoted on both the DOI and the Department of Health Care Policy and Financing’s (HCPF) websites, and each department can seek gifts, grants, and donations for this purpose. The bill requires that insurance carriers providing coverage for epinephrine auto-injectors must cap the total cost to the covered person at $60 for a 2-pack of the injectors. Additionally, pharmacies dispensing injectors through the affordability program are permitted to collect a copayment of no more than $60 for a 2-pack of injectors to cover their processing and dispensing costs. DORA may also use enforcement powers to ensure compliance and promulgate rules as necessary.
11:08:06 AM  
Committee members asked Senator Roberts questions.
11:10:14 AM  
Sam Gilman, representing
themself, testified in support of the bill.




Ms. Isabel Cruz,
representing Colorado Consumer Health Initiative, testified in support
of the bill.




Zach Neumann,
representing Community Economic Defense Project, testified in support of
the bill. Zach Neumann distributed a handout to the committee (Attachment
E).




Committee members
asked the panel questions.
11:44:34 AM  
Jackson Pugh, representing
themself, testified in a neutral position on the bill.




Keri Pugh, representing
themself, testified in support of the bill.




Michael Brzica,
representing Teva Pharmaceuticals, testified to amend the bill.




Dr. Ky Davis,
representing RxPlus Pharmacies, testified in support of the bill.




Committee members
asked the panel questions.
12:11:47 PM  
The committee recessed.
12:42:59 PM  
The committee resumed.
12:43:02 PM  
Senator Roberts introduced
amendments L.007 and L.008 (Attachments F and G).

12:44:15 PM  
Committee members
asked questions regarding amendment L.008 (Attachment G).



12:45:05 PM
Motion Adopt amendment L.008 (Attachment G).
Moved Ginal
Seconded
Buckner
Cutter
Jaquez Lewis
Mullica
Rich
Smallwood
Will
Ginal
Fields
YES: 0   NO: 0   EXC: 0   ABS:  0   FINAL ACTION:  Pass Without Objection
12:45:27 PM  
Committee members
asked questions regarding amendment L.007 (Attachment F).



12:55:45 PM
Motion Adopt amendment L.007 (Attachment F).
Moved Ginal
Seconded
Buckner
Cutter
Jaquez Lewis
Mullica
Rich
Smallwood
Will
Ginal
Fields
YES: 0   NO: 0   EXC: 0   ABS:  0   FINAL ACTION:  Pass Without Objection
12:56:19 PM  
Senator Mullica introduced
amendment L.009 (Attachment H). Committee members and the bill sponsor
discussed amendment L.009.


01:02:50 PM
Motion Adopt amendment L.009 (Attachment H).
Moved Mullica
Seconded
Buckner No
Cutter No
Jaquez Lewis No
Mullica Yes
Rich Yes
Smallwood Yes
Will Yes
Ginal Yes
Fields No
YES: 5   NO: 4   EXC: 0   ABS:  0   FINAL ACTION:  PASS
01:03:23 PM  
Senator Roberts provided closing remarks.


01:05:14 PM
Motion Refer House Bill 23-1002, as amended, to the Committee on Appropriations.
Moved Ginal
Seconded
Buckner Yes
Cutter Yes
Jaquez Lewis Yes
Mullica Yes
Rich Yes
Smallwood No
Will Yes
Ginal Yes
Fields Yes
Final YES: 8   NO: 1   EXC: 0   ABS:  0   FINAL ACTION:  PASS






Colorado legislature email addresses ending in @state.co.us are no longer active. Please replace @state.co.us with @coleg.gov for Colorado legislature email addresses. Details

The effective date for bills enacted without a safety clause is August 7, 2024, if the General Assembly adjourns sine die on May 8, 2024, unless otherwise specified. Details